MCED blood test demonstrates high specificity, strong predictive value, and increased early canc... скачать в хорошем качестве

MCED blood test demonstrates high specificity, strong predictive value, and increased early canc...

Dr Nima Nabavizadeh talks to ecancer at ESMO 2025 about data he presented. The PATHFINDER II study evaluated the 'Galleri' multi-cancer early detection (MCED) blood test in over 35,000 adults aged 50 and older with no known cancer. Among 23,161 participants with one-year follow-up, 0.93% had a positive result. The test showed high specificity (99.6%), positive predictive value (61.6%), and accurate cancer origin prediction (91.7%). Sensitivity was 73.7% for 12 major cancers and 40.4% overall. MCED testing detected 133 cancers, over half at early stages, and most without existing screening options. With few unnecessary invasive procedures (0.6%), MCED testing increased early cancer detection.